Vidya Mave, MD, MPH

CRS:

BJMC

Role:

Investigators

Position:

CRS Leader and Director

Email:

vidyamave@gmail.com

Vidya Mave, MD, MPH, is a Research Associate faculty member at the Johns Hopkins School of Medicine as well as Director and Clinical Research Site (CRS) Leader of the Byramjee Jeejeebhoy Government Medical College (BJGMC)-JHU Clinical Trials Unit (CTU), a collaborative research partnership in Pune, India that is part of the world’s largest HIV therapeutic trial networks (the AIDS Clinical Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS clinical Trial Network [IMPAACT]).

Dr. Mave has more than 12 years of combined experience in clinical practice, education and research in infectious diseases and has published over 20 peer-reviewed research publications. Following a short tenure as Assistant Professor of Infectious Diseases at Tulane University School of Medicine, Dr. Mave joined the Johns Hopkins CCGHE. She now coordinates all clinical research activities at the BJGMC-JHU CTU, which conducts phase I, II, and III clinical trials of therapeutic drug interventions for HIV and co-morbid infections, including TB and hepatitis, in adults (including pregnant women) and children. Her research interests include the epidemiology of latent TB infection among pregnant women, the role of Vitamin D levels in pediatric TB infection and patterns of TB drug resistance in Pune. In addition, Dr. Mave has mentored more than 16 pre- and postdoctoral trainees from Hopkins and is available to mentor trainees participating in the BJGMC-JHU HIV-TB Fogarty Research Training Program.

Dr. Mave received a MBBS in Medicine from Karnatak University, Dhjarwad, India, and a Masters in Public Health from Tulane University. She completed her Internal Medicine training at St. Barnabas Hospital in New York followed by a post-doctoral fellowship in Infectious Diseases at Tulane University and Long Island Jewish Medical Center. Dr. Mave is Board Certified in Internal Medicine and Infectious Diseases by the American Board of Internal Medicine.

  • Co-Investigator in IMPAACT 2001, IMPAACT 1073, ACTG 5302, ACTG5362 (Clo-fast), PHOENIx study
  • Member, End-Organ Disease and Inflammation Transformative Science Group (Feb2016-Nov2017)
  • Member, Tuberculosis Transformative Science Group
  • Member TBSC

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More